{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-019652","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2023-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.660175+00:00","generated_at":"2026-06-14T10:30:16.314865+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BriaCell to spin out pre-clinical assets into BriaPro; shareholders get 1 SpinCo share per each held","bullets":["SpinCo to acquire Bria-TILsRx™ and PKCδ inhibitors from BriaCell.","Each BriaCell shareholder receives 1 SpinCo share and 1 new BriaCell share; warrants adjusted similarly.","Shareholders will own 33.33% of SpinCo; BriaCell retains 66.67%.","Special shareholder meeting scheduled for July 2023; closing targeted by August 2023.","Conditions: shareholder vote, court orders, TSX and Nasdaq approvals; board unanimously supports."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-019652","json":"https://secwatch.observer/filing/0001493152-23-019652.json","markdown":"https://secwatch.observer/filing/0001493152-23-019652.md","text":"https://secwatch.observer/filing/0001493152-23-019652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223019652/0001493152-23-019652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223019652/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T10:30:16.314865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"973d6dea5dfc041f55a784dee8ef87e7bdf4c33c","claim":"BriaCell Therapeutics Corp. entered into Arrangement Agreement with BriaPro Therapeutics Corp. valued at spin-out of pre-clinical pipeline assets in exchange for SpinCo common shares; SpinCo Shares represe (effective 2023-05-24).","evidence_excerpt":"On May 24, 2023, BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) entered into an Arrangement Agreement (the “Arrangement Agreement”) with BriaPro Therapeutics Corp., a British Columbia corporation and wholly-owned subsidiary of the Company (“SpinCo”), pursuant to which the Company will spin out certain of its pre-clinical pipeline assets , including Bria-TILsRxTM and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (collectively, the “SpinCo Assets”), to SpinCo by way of a court-approved statutory plan of arrangement under Section 288 of the Business Corporations Act (British Columbia) (the “Arrangement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223019652/0001493152-23-019652-index.htm","confidence":0.97,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"BriaPro Therapeutics Corp."},{"label":"Value","value":"spin-out of pre-clinical pipeline assets in exchange for SpinCo common shares; SpinCo Shares represe"},{"label":"Effective","value":"2023-05-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}